Mesenchymal Stromal Cells Mediate Clinically Unpromising but Favourable Immune Responses in Kidney Transplant Patients
Open Access
- 15 February 2022
- journal article
- research article
- Published by Hindawi Limited in Stem Cells International
- Vol. 2022, 1-17
Abstract
Background. Allograft rejection postkidney transplantation (KTx) is a major clinical challenge despite increased access to a healthcare system and improvement in immunosuppressive (IS) drugs. In recent years, mesenchymal stromal cells (MSCs) have aroused considerable interest in field of transplantation due to their immunomodulatory and regenerative properties. This study was aimed at investigating safety, feasibility, and immunological effects of autologous MSCs (auto-MSCs) and allogeneic MSCs (allo-MSCs) as a complement to IS drug therapy in KTx patients. Methods. 10 patients undergoing KTx with a living-related donor were analysed along with 5 patients in the control group. Patients were given auto-MSCs or allo-MSCs at two time points, i.e., one day before transplant (D-0) and 30 days after transplant (D-30) at the rate of 1.0- MSCs per kg body weight in addition to immunosuppressants. Patients were followed up for 2 years, and 29 immunologically relevant lymphocyte subsets and 8 cytokines and important biomarkers were analysed at all time points. Results. Patients displayed no signs of discomfort or dose-related toxicities in response to MSC infusion. Flow cytometric analysis revealed an increase in B regulatory lymphocyte populations and nonconventional T regulatory cells and a decrease in T effector lymphocyte proportions in auto-MSC-infused patients. No such favourable immune responses were observed in all MSC-infused patients. Conclusion. This study provides evidence that auto-MSCs are safe and well tolerated. This is the first ever report to compare autologous and allogeneic MSC infusion in KTx patients. Importantly, our data demonstrated that MSC-induced immune responses in patients did not completely correlate with clinical outcomes. Our findings add to the current perspective of using MSCs in KTx and explore possibilities through which donor/recipient chimerism can be achieved to induce immune tolerance in KTx patients.Keywords
This publication has 32 references indexed in Scilit:
- Immunosuppressive Drug TherapyCold Spring Harbor Perspectives in Medicine, 2013
- Natural regulatory T cells are resistant to calcium release-activated calcium (CRAC/ORAI) channel inhibitionInternational Immunology, 2013
- Autologous Bone Marrow-Derived Mesenchymal Stromal Cells for the Treatment of Allograft Rejection After Renal Transplantation: Results of a Phase I StudyStem Cells Translational Medicine, 2013
- Changes in the number of circulating TCM and TEM subsets in renal transplantation: relationship with acute rejection and induction therapyKidney International Supplements, 2011
- Autologous Mesenchymal Stromal Cells and Kidney TransplantationClinical Journal of the American Society of Nephrology, 2011
- Generation of Donor-Specific Regulatory T-Cell Function in Kidney Transplant PatientsTransplantation, 2009
- Double‐negative regulatory T cells induce allotolerance when expanded after allogeneic haematopoietic stem cell transplantationBritish Journal of Haematology, 2008
- Kidney Transplantation as Primary Therapy for End-Stage Renal DiseaseClinical Journal of the American Society of Nephrology, 2008
- Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statementCytotherapy, 2006
- PREDICTING GLOMERULAR FILTRATION RATE AFTER KIDNEY TRANSPLANTATIONTransplantation, 1995